Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 5.58B +50.8% |
| Revenue (ttm) | 618.07M +44.0% |
| Net Income | -860.21M |
| EPS | -15.34 |
| Shares Out | 64.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,139,627 |
| Open | 81.01 |
| Previous Close | 81.35 |
| Day's Range | 81.01 - 87.79 |
| 52-Week Range | 63.23 - 130.00 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 145.79 (+69.5%) |
| Est. Earnings | Nov 3, 2026 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $145.79, which is an increase of 69.50% from the latest price.
News
Mirum Pharmaceuticals price target raised to $155 from $135 at RBC Capital
RBC Capital raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $155 from $135 and keeps an Outperform rating on the shares as part of a broader research note…
Mirum Pharmaceuticals price target raised to $130 from $123 at Baird
Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $123 and keeps an Outperform rating on the shares.
Mirum Pharmaceuticals price target raised to $160 from $145 at Citi
Citi raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $160 from $145 and keeps a Buy rating on the shares. The firm cites the positive Phase 3 readout…
Mirum Pharmaceuticals price target raised to $195 from $140 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $195 from $140 and keeps a Buy rating on the shares. The company reported positive topline results from…
Mirum's liver infection drug lowers virus levels in late-stage study
Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study.
Mirum Pharmaceuticals Transcript: Study result
Phase III AZURE-1 results show brelovitug achieved rapid, significant virologic and ALT responses in chronic hepatitis delta, with strong safety and efficacy across advanced disease. Commercial outlook is robust, with peak sales guidance raised to $1B and further data from AZURE-4 expected soon.
Mirum Pharmaceuticals Slides: Study result
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 28, 2026.
Mirum Pharmaceuticals Press release: Study result
Mirum Pharmaceuticals issued a press release on September 28, 2026, disclosing material business information to investors.
Mirum Pharmaceuticals says primary endpoint met in Phase 3 AZURE-1 study
Mirum Pharmaceuticals (MIRM) announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to ...
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.
Mirum Pharmaceuticals Slides: Corporate presentation
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 28, 2026.
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic HDV on September 28, 2026.
Mirum Pharmaceuticals, Incyte announce FDA approval of Atebrioz
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged...
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progre...
US FDA approves Mirum's drug for rare bone disorder
The US Food and Drug Administration has approved Mirum Pharmaceuticals' drug to treat a rare bone disorder, the regulator said on Friday.
Mirum Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong commercial growth is driven by rare disease medicines, with LIVMARLI and the bile acid portfolio expanding into new patient populations. Multiple late-stage pipeline readouts and launches are expected next year, while regulatory engagement continues for volixibat in PSC and PBC. The business remains focused on rare disease opportunities and poised for further gains.
Mirum Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Strong Q2 revenue and raised guidance reflect robust commercial growth, especially for LIVMARLI in rare liver diseases. Multiple near-term clinical milestones, commercial team expansion, and international growth are expected to drive further momentum.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026
Multiple late-stage clinical readouts and regulatory milestones are expected in the next two quarters, including pivotal data for HDV, FOP, and cholestatic pruritus programs. AI is broadly integrated to enhance productivity, and the company is expanding its rare disease portfolio with a focus on underdiagnosed populations.
Mirum Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A diversified rare disease portfolio is driving strong commercial growth, with multiple near-term clinical and regulatory catalysts expected. LIVMARLI expansion, new launches, and pipeline progress position the business for a financial inflection point and potential profitability in the coming years.
Mirum Pharmaceuticals appoints Myers as Chief Medical Officer
Mirum Pharmaceuticals (MIRM) announced the appointment of Rob Myers, M.D., as Chief Medical Officer, effective September 21, 2026. Dr. Myers will join the company’s leadership team and lead Mirum’s gl...
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum Pharmaceuticals price target lowered to $123 from $129 at Baird
Baird lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $123 from $129 and keeps an Outperform rating on the shares.
Mirum Pharmaceuticals price target lowered to $140 from $145 at TD Cowen
TD Cowen lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $140 from $145 and keeps a Buy rating on the shares. The firm said Management again raised guidance…